

|   |  |                             |                   |
|---|--|-----------------------------|-------------------|
| <b>LIST OF REFERENCES CITED BY APPLICANT</b><br>(Use several sheets if necessary) |  | <b>Application Number</b>   | 10/657,363        |
|   |  | <b>Filing Date</b>          | September 8, 2003 |
|   |  | <b>First Named Inventor</b> | Young et al.      |
|   |  | <b>Art Unit</b>             | 1648              |
|   |  | <b>Examiner Name</b>        | Hill, Myron G.    |
|   |  | <b>Attorney Docket No.</b>  | 10271-159-999     |

**U.S. PATENT DOCUMENTS**

| <b>*Examiner Initials</b> | <b>Cite No.</b> | <b>Document Number – Kind Code</b> | <b>Publication Date mm/dd/yyyy</b> | <b>Name of Patentee or Applicant of Cited Document</b> | <b>Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear</b> |
|---------------------------|-----------------|------------------------------------|------------------------------------|--|--|
|                           | J01             | 4,517,304                          | 05/14/1985                         | Stott et al.   |  |
|                           | J02             | 4,526,938                          | 07/2/1985                          | Churchhill et al.                                      |  |
|                           | J03             | 4,659,563                          | 04/21/1987                         | Dobkin   |  |
|                           | J04             | 4,717,766                          | 01/05/1988                         | Dobkin   |  |
|                           | J05             | 4,760,026                          | 07/26/1988                         | Lennox et al.  |  |
|                           | J06             | 4,853,326                          | 08/01/1989                         | Quash et al.   |  |
|                           | J07             | 4,917,893                          | 04/17/1990                         | Okada et al.   |  |
|                           | J08             | 5,071,758                          | 12/10/1991                         | Stott et al.   |  |
|                           | J09             | 5,128,326                          | 07/07/1992                         | Balazs et al.  |  |
|                           | J10             | 5,137,804                          | 08/11/1992                         | Greene et al.  |  |
|                           | J11             | 5,149,650                          | 09/22/1992                         | Wertz et al.   |  |
|                           | J12             | 5,183,657                          | 02/2/1993                          | Buurman  |  |
|                           | J13             | 5,194,595                          | 03/16/1993                         | Wathen   |  |
|                           | J14             | 5,219,996                          | 06/15/1993                         | Bodmer et al.  |  |
|                           | J15             | 5,223,254                          | 06/29/1993                         | Paradiso et al.  |  |
|                           | J16             | 5,240,694                          | 08/31/1993                         | Gwaltney, Jr.  |  |
|                           | J17             | 5,271,927                          | 12/21/1993                         | Parker et al.  |  |
|                           | J18             | 5,279,935                          | 01/18/1994                         | Nycz   |  |
|                           | J19             | 5,288,630                          | 02/22/1994                         | Wathen   |  |
|                           | J20             | 5,332,567                          | 07/26/1994                         | Goldenberg   |  |
|                           | J21             | 5,332,805                          | 07/26/1994                         | Carey et al.   |  |
|                           | J22             | 5,340,926                          | 08/23/1994                         | Lowe et al.  |  |
|                           | J23             | 5,354,554                          | 10/11/1994                         | Rhind  |  |
|                           | J24             | 5,391,478                          | 02/21/1995                         | Greene et al.  |  |
|                           | J25             | 5,411,749                          | 05/2/1995                          | Mayo et al.  |  |
|                           | J26             | 5,412,077                          | 05/2/1995                          | Siber et al.   |  |

LAI-3012585v2

|   |                        |
|---|------------------------|
| <b>EXAMINER<br/>SIGNATURE</b>   | <b>DATE CONSIDERED</b> |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                        |

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

|                             |                   |
|-----------------------------|-------------------|
| <b>Application Number</b>   | 10/657,363        |
| <b>Filing Date</b>          | September 8, 2003 |
| <b>First Named Inventor</b> | Young et al.      |
| <b>Art Unit</b>             | 1648              |
| <b>Examiner Name</b>        | Hill, Myron G.    |
| <b>Attorney Docket No.</b>  | 10271-159.999     |

**U.S. PATENT DOCUMENTS**

| <b>*Examiner Initials</b> | <b>Cite No.</b> | <b>Document Number – Kind Code</b> | <b>Publication Date mm/dd/yyyy</b> | <b>Name of Patentee or Applicant of Cited Document</b> | <b>Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear</b> |
|---------------------------|-----------------|------------------------------------|------------------------------------|--|--|
|                           | J27             | 5,418,136                          | 05/23/1995                         | Miller et al.  |  |
|                           | J28             | 5,422,097                          | 06/06/1995                         | Gwaltney Jr.   |  |
|                           | J29             | 5,424,189                          | 06/13/1995                         | Oberst et al.  |  |
|                           | J30             | 5,468,606                          | 11/21/1995                         | Bogart et al.  |  |
|                           | J31             | 5,470,736                          | 11/28/1995                         | Verma et al.   |  |
|                           | J32             | 5,476,997                          | 12/19/1995                         | Kaneshima et al.                                       |  |
|                           | J33             | 5,484,893                          | 01/16/1996                         | Parker et al.  |  |
|                           | J34             | 5,506,209                          | 04/09/1996                         | Mukerji et al.   |  |
|                           | J35             | 5,518,725                          | 05/21/1996                         | Daynes et al.  |  |
|                           | J36             | 5,530,102                          | 06/25/1996                         | Gristina et al.  |  |
|                           | J37             | 5,538,733                          | 07/23/1996                         | Emery et al.   |  |
|                           | J38             | 5,538,952                          | 07/23/1996                         | Mukerji et al.   |  |
|                           | J39             | 5,624,821                          | 04/29/1997                         | Winter   |  |
|                           | J40             | 5,648,260                          | 07/15/1997                         | Winter   |  |
|                           | J41             | 5,679,377                          | 10/21/1997                         | Bernstein et al.                                       |  |
|                           | J42             | 5,855,913                          | 01/05/1999                         | Hanes et al.   |  |
|                           | J43             | 5,874,064                          | 02/23/1999                         | Edwards et al.   |  |
|                           | J44             | 5,912,015                          | 06/15/1999                         | Bernstein et al.                                       |  |
|                           | J45             | 5,916,597                          | 06/29/1999                         | Lee et al.   |  |
|                           | J46             | 5,934,272                          | 08/10/1999                         | Lloyd et al.   |  |
|                           | J47             | 5,985,309                          | 11/16/1999                         | Edwards et al.   |  |
|                           | J48             | 5,985,320                          | 11/16/1999                         | Edwards et al.   |  |
|                           | J49             | 5,989,463                          | 11/23/1999                         | Tracy et al.   |  |
|                           | J50             | 6,019,968                          | 02/01/2000                         | Platz et al.   |  |
|                           | J51             | 6,121,022                          | 09/19/2000                         | Presta   |  |
|                           | J52             | 6,194,551                          | 02/27/2001                         | Idusogie   |  |

LAI-3012585v2

|   |                        |
|---|------------------------|
| <b>EXAMINER SIGNATURE</b>   | <b>DATE CONSIDERED</b> |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                        |

|   |  |                             |                   |
|---|--|-----------------------------|-------------------|
| <b>LIST OF REFERENCES CITED BY APPLICANT</b><br>(Use several sheets if necessary) |  | <b>Application Number</b>   | 10/657,363        |
|   |  | <b>Filing Date</b>          | September 8, 2003 |
|   |  | <b>First Named Inventor</b> | Young et al.      |
|   |  | <b>Art Unit</b>             | 1648              |
|   |  | <b>Examiner Name</b>        | Hill, Myron G.    |
|   |  | <b>Attorney Docket No.</b>  | 10271-159-999     |

**U.S. PATENT DOCUMENTS**

| <b>*Examiner Initials</b> | <b>Cite No.</b> | <b>Document Number – Kind Code</b> | <b>Publication Date mm/dd/yyyy</b> | <b>Name of Patentee or Applicant of Cited Document</b> | <b>Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear</b> |
|---------------------------|-----------------|------------------------------------|------------------------------------|--|--|
|                           | J53             | 6,277,375                          | 08/21/2001                         | Ward   |  |
|                           | J54             | 6,519,948                          | 02/18/2003                         | Zorn   |  |
|                           | J55             | 6,528,624                          | 03/04/2003                         | Idusogic   |  |
|                           | J56             | 6,538,124                          | 03/25/2003                         | Idusogic   |  |
|                           | J57             | 6,565,888                          | 05/20/2003                         | Tracy et al.   |  |
|                           | J58             | 6,737,056                          | 05/18/2004                         | Presta   |  |
|                           | J59             | 7,083,784                          | 08/01/2006                         | Dall'Acqua   |  |
|                           | J60             | 7,416,726                          | 08/26/2008                         | Ravetch  |  |
|                           | J61             | 2004-0131609                       | 07/08/2004                         | Young et al.   |  |
|                           | J62             | 2004-0002587                       | 01/01/2004                         | Watkins  |  |
|                           | J63             | US 2006-0099220                    | 05/11/2006                         | Tous et al.  |  |

**FOREIGN PATENT DOCUMENTS**

| <b>*Examiner Initials</b> | <b>Cite No.</b> | <b>Foreign Patent Document Country Code, Number, Kind Code (if known)</b> | <b>Publication Date mm/dd/yyyy</b> | <b>Name of Patentee or Applicant of Cited Document</b> | <b>Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear</b> | <b>T</b> |
|---------------------------|-----------------|---|------------------------------------|--|--|----------|
|                           | K01             | AU 2002219944   | 02/21/2008                         | MedImmune, Inc.  |  |          |
|                           | K02             | EP 0413622  | 02/20/1991                         | Rhone Poulenc Rorer SA                                 |  |          |
|                           | K03             | EP 0451216  | 01/24/1996                         | Protein Design Labs Inc                                |  |          |
|                           | K04             | EP 0682040  | 11/15/1995                         | Protein Design Labs Inc                                |  |          |
|                           | K05             | WO 00/42072   | 07/20/2000                         | Genentech Inc.   |  |          |
|                           | K06             | WO 01/58957   | 08/16/2001                         | Lexigen Pharm. Corp.                                   |  |          |
|                           | K07             | WO 03/054213  | 07/03/2003                         | Genentech Inc.   |  |          |
|                           | K08             | WO 04/010935  | 02/05/2004                         | MedImmune  |  |          |
|                           | K09             | WO 04/029207  | 04/08/2004                         | Xencor et al.  |  |          |
|                           | K10             | WO 04/035752  | 04/29/2004                         | Protein Design Labs. Inc.                              |  |          |

LA1-3012585v2

|   |                        |
|---|------------------------|
| <b>EXAMINER SIGNATURE</b>   | <b>DATE CONSIDERED</b> |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                        |

|   |  |                             |                   |
|---|--|-----------------------------|-------------------|
| <b>LIST OF REFERENCES CITED BY APPLICANT</b><br>(Use several sheets if necessary) |  | <b>Application Number</b>   | 10/657,363        |
|   |  | <b>Filing Date</b>          | September 8, 2003 |
|   |  | <b>First Named Inventor</b> | Young et al.      |
|   |  | <b>Art Unit</b>             | 1648              |
|   |  | <b>Examiner Name</b>        | Hill, Myron G.    |
|   |  | <b>Attorney Docket No.</b>  | 10271-159-999     |

**FOREIGN PATENT DOCUMENTS**

| <b>*Examiner Initials</b> | <b>Cite No.</b> | <b>Foreign Patent Document Country Code, Number, Kind Code (if known)</b> | <b>Publication Date mm/dd/yyyy</b> | <b>Name of Patentee or Applicant of Cited Document</b>                       | <b>Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear</b> | <b>T</b> |
|---------------------------|-----------------|---|------------------------------------|--|--|----------|
|                           | K11             | WO 06/034292  | 03/30/2006                         | MedImmune  |  |          |
|                           | K12             | WO 90/07861   | 07/26/1990                         | Protein Design Labs, Inc.  |  |          |
|                           | K13             | WO 91/05548   | 05/02/1991                         | Pitman-Moore Inc.  |  |          |
|                           | K14             | WO 93/05796   | 04/01/1993                         | The Scripps Research Institute   |  |          |
|                           | K15             | WO 93/15200   | 08/05/1993                         | Rhone Poulenc Rorer SA   |  |          |
|                           | K16             | WO 93/19197   | 09/30/1993                         | Immunet  |  |          |
|                           | K17             | WO 93/20210   | 10/14/1993                         | Scotgen Limited  |  |          |
|                           | K18             | WO 95/04081   | 02/09/1995                         | Oravax, Inc.   |  |          |
|                           | K19             | WO 96/20698   | 07/11/1996                         | The Board of Regents acting for and on behalf of The University Of Michigan  |  |          |
|                           | K20             | WO 97/32572   | 09/12/1997                         | The Penn State Research Foundation of Massachusetts Institute Of Technology  |  |          |
|                           | K21             | WO 97/34631   | 09/25/1997                         | Board Of Regents, The University Of Texas System Ward                        |  |          |
|                           | K22             | WO 97/44013   | 11/27/1997                         | Massachusetts Institute Of Technology<br>The Penn State Research Foundation  |  |          |
|                           | K23             | WO 98/23289   | 06/04/1998                         | The General Hospital Corp.   |  |          |
|                           | K24             | WO 98/31346   | 07/23/1998                         | Massachusetts Institute Of Technology;<br>The Penn State Research Foundation |  |          |
|                           | K25             | WO 99/15154   | 04/01/1999                         | Alkermes Controlled Therapeutics, Inc.                                       |  |          |
|                           | K26             | WO 99/20253   | 04/29/1999                         | Bioglan Therapeutics AB  |  |          |
|                           | K27             | WO 99/51642   | 10/14/1999                         | Genentech Inc.   |  |          |
|                           | K28             | WO 99/66903   | 12/29/1999                         | Advanced Inhalation Research, Inc.   |  |          |
|                           | K29             | WO 07/002543  | 01/04/2007                         | MedImmune  |  |          |
|                           | K30             | WO 09/003019  | 12/31/2008                         | MedImmune  |  |          |

LAI-3012585v2

|   |                        |
|---|------------------------|
| <b>EXAMINER<br/>SIGNATURE</b>   | <b>DATE CONSIDERED</b> |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                        |

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

|                             |                   |
|-----------------------------|-------------------|
| <b>Application Number</b>   | 10/657,363        |
| <b>Filing Date</b>          | September 8, 2003 |
| <b>First Named Inventor</b> | Young et al.      |
| <b>Art Unit</b>             | 1648              |
| <b>Examiner Name</b>        | Hill, Myron G.    |
| <b>Attorney Docket No.</b>  | 10271-159-999     |

**NON PATENT LITERATURE DOCUMENTS**

| *Examiner Initials | Cite No.  | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                | T |
|--------------------|---|---|---|
| L01                | Adams et al., 1998.   | Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies, <i>Cancer Res.</i> 58(3):485-90.   |   |
| L02                | American Academy of Pediatrics Committee on Infectious Diseases | Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection, <i>Pediatrics</i> . 1993 Sep;92(3):501-4.   |   |
| L03                | Bennett et al., 2007.   | Immunopathogenesis of Respiratory Syncytial Virus Bronchiolitis, <i>JID</i> , 195:1532-1540.  |   |
| L04                | Bentley and Rabbits, 1980.                                      | Human immunoglobulin variable region genes-- DNA Sequences of Two V Kappa Genes and a Pseudogene, <i>Nature</i> 288: 730-733.   |   |
| L05                | Boulianne et al., 1984.   | Production of functional chimaeric mouse/human antibody, <i>Nature</i> 312(5995):643-646.   |   |
| L06                | Carson and Freiman, 1986.                                       | Human lymphocyte hybridomas and monoclonal antibodies, <i>Adv. Immunol.</i> 38:275-311.   |   |
| L07                | Chothia et al., 1998.   | Structural determinants in the sequences of immunoglobulin variable domain, <i>J Mol Biol.</i> 278(2):457-79.   |   |
| L08                | Cleek et al., 1997.   | Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application, <i>Pro. Int'l Symp. Control. Rel. Bioact. Mater.</i> 24: 853-854.  |   |
| L09                | Colman, 1994.   | Effects of amino acid sequence changes on antibody-antigen interactions; <i>Res Immunol.</i> 145(1):33-6.   |   |
| L10                | Crowe et al., 1994.   | Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice, <i>Proc. Natl. Acad. Sci. USA</i> , 91:1386-1390.                                  |   |
| L11                | DeVincenzo, 2005.   | Factors Predicting Childhood Respiratory Syncytial Virus Severity. What They Indicate About Pathogenesis. <i>The Pediatric Infectious Disease Journal</i> , 24(11):S177-S183.   |   |
| L12                | Downham et al., 1976.   | Breast-feeding protects against respiratory syncytial virus infections, <i>Br Med J.</i> 2(6030):274-6.   |   |
| L13                | Edelman et al., 1969.   | The Covalent Structure of an Entire gammaG Immunoglobulin Molecule. <i>PNAS</i> 63:78-85.   |   |
| L14                | Fields et al., 1990.  | Fields Virology, 2nd Ed., Vol. 1, Raven Press, NY p. 1045-1072.   |   |
| L15                | Garvis and Gray, 1980.  | Outbreak of Respiratory Syncytial Virus Infection in the Elderly, <i>Br Med J.</i> 281(6250):1253-4.  |   |
| L16                | Gillies et al., 1989.   | High-level expression of chimeric antibodies using adapted cDNA variable region cassettes, <i>J. Immunol. Methods</i> , 125:191-202.  |   |
| L17                | Hemming et al., 1988.   | Topically Administered Immunoglobulin Reduces Pulmonary Respiratory Syncytial Virus Shedding in Owl Monkeys, <i>Antimicrobial Agents and Chemotherapy</i> , 32(8):1269-1270.  |   |
| L18                | Howard et al., 1989.  | Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits, <i>J Neurosurg.</i> 71(1):105-12.  |   |
| L19                | Hudson and Souriau, 2003.                                       | Engineered Antibodies, <i>Nature Medicine</i> 9(1):129-34.  |   |
| L20                | Ichiyoshi et al., 1995.   | A human anti-insulin IgG autoantibody apparently arises through clonal selection from an insulin-specific "germ-line" natural antibody template. Analysis by V gene segment reassortment and site-directed mutagenesis, <i>J. Immunol.</i> 154(1):226-38. |   |
| L21                | Jackson et al., 1998.   | Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives, <i>Br. J. Cancer</i> 78(2):181-8.   |   |

LAI-3012585v2

|   |                        |
|---|------------------------|
| <b>EXAMINER SIGNATURE</b>   | <b>DATE CONSIDERED</b> |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                        |

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

|                             |                   |
|-----------------------------|-------------------|
| <b>Application Number</b>   | 10/657,363        |
| <b>Filing Date</b>          | September 8, 2003 |
| <b>First Named Inventor</b> | Young et al.      |
| <b>Art Unit</b>             | 1648              |
| <b>Examiner Name</b>        | Hill, Myron G.    |
| <b>Attorney Docket No.</b>  | 10271-159-999     |

**NON PATENT LITERATURE DOCUMENTS**

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|--|---|
|                    | L22      | Johnson et al., 1987. The G Glycoprotein of Human Respiratory Syncytial Viruses of Subgroups A and B: Extensive Sequence Divergence Between Antigenically Related Proteins, Proc Natl Acad Sci U S A. 84(16):5625-9.                       |   |
|                    | L23      | Johnson et al., 1991. Development of humanized monoclonal antibodies which neutralize respiratory syncytial virus, J. Cellular Biochem. Suppl. 15E. P.120, Abstract No. 108.   |   |
|                    | L24      | Kapikian et al., 1969. An Epidemiologic Study of Altered Clinical Reactivity to Respiratory Syncytial (RS) Virus Infection in Children Previously Vaccinated With an Inactivated RS Virus Vaccine, Am J Epidemiol. 89(4):405-21.           |   |
|                    | L25      | Levy et al., 1985. Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-release Diphosphonate, Science. 228(4696):190-2.  |   |
|                    | L26      | Liu et al., 1987. Expression of mouse:human immunoglobulin heavy-chain cDNA in lymphoid cells, Gene 54(1):33-40.   |   |
|                    | L27      | Maynard et al., 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity, Nat. Biotechnol. 20(6):597-601.   |   |
|                    | L28      | Mejias et al., 2005. Respiratory syncytial virus infections: Old challenges and new opportunities, Ped. Infect. Dis. J. 24: S189-S197.   |   |
|                    | L29      | Mejias et al., 2005. Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus Potency, Antimicrobial Agents and Chemotherapy Vol. 49, No. 11: 4700-4707.  |   |
|                    | L30      | Morrison et al., 1984. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA 81(21):6851-6855.   |   |
|                    | L31      | Morrison et al., 1985. Transfectedomas provide novel chimeric antibodies, Science 229(4719):1202-1207.   |   |
|                    | L32      | Murphy et al., 1994. An Update on Approaches to the Development of Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) Vaccines, Virus Res. 32(1):13-36.   |   |
|                    | L33      | Ning et al., 1996. Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained Release Gel, Radiotherapy and Oncology 39: 179-89.  |   |
|                    | L34      | Ogra et al., 1988. Respiratory Syncytial Virus Infection and the Immunocompromised Host, Pediatr Infect Dis J. 1988 Apr;(74):246-9.  |   |
|                    | L35      | Orkin and Motulsky, Report and recommendations of the panel to assess the NIH investment in research on gene therapy, available from <a href="http://www.nih.gov/news/panelrep.html">http://www.nih.gov/news/panelrep.html</a> (1995).     |   |
|                    | L36      | Padlan, 1991. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, Mol. Immunol. 28(4/5):489-498.   |   |
|                    | L37      | Pohl et al., 1992. Respiratory Syncytial Virus Infections in Pediatric Liver Transplant Recipients, J Infect Dis. 165(1):166-9.  |   |
|                    | L38      | Press et al., 1970. The Amino Acid Sequences of the Fd Fragments of Two Human Gamma-I Heavy chains, Biochem J. 117(4):641-60.  |   |
|                    | L39      | Prince et al., 1987. Effectiveness of Topically Administered Neutralizing Antibodies in Experimental Immunotherapy of Respiratory Syncytial Virus Infection in Cotton Rats, Journal of Virology, 61(6):1851-1854.                          |   |
|                    | L40      | Riechmann et al., 1988. Reshaping human antibodies for therapy. Nature. 332(6162):323-7.   |   |
|                    | L41      | Ruuskanen et al., 1993. Respiratory syncytial virus, Curr Probl Pediatr. 23(2):50-79.  |   |

LAI-3012585v2

|   |                        |
|---|------------------------|
| <b>EXAMINER SIGNATURE</b>   | <b>DATE CONSIDERED</b> |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                        |

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

|                             |                   |
|-----------------------------|-------------------|
| <b>Application Number</b>   | 10/657,363        |
| <b>Filing Date</b>          | September 8, 2003 |
| <b>First Named Inventor</b> | Young et al.      |
| <b>Art Unit</b>             | 1648              |
| <b>Examiner Name</b>        | Hill, Myron G.    |
| <b>Attorney Docket No.</b>  | 10271-159-999     |

**NON PATENT LITERATURE DOCUMENTS**

| <b>*Examiner Initials</b> | <b>Cite No.</b> | <b>Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>                      | <b>T</b> |
|---------------------------|-----------------|--|----------|
|                           | L42             | Sauder et al., 1989. A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery. <i>N Engl J Med.</i> 321(9):574-9.  |          |
|                           | L43             | Scott et al., 1985. Cellular reactivity to respiratory syncytial virus in human colostrum and breast milk. <i>J Med Virol.</i> 17(1):83-93.  |          |
|                           | L44             | Sefton, 1987. Implantable Pumps, <i>CRC Crit. Rev. Biomed. Eng.</i> 14:201-240.  |          |
|                           | L45             | Sevier et al., 1981. Monoclonal antibodies in clinical immunology. <i>Clin Chem.</i> 27(11):1797-806.  |          |
|                           | L46             | Song et al., 1995. Antibody Mediated Lung Targeting of Long-Circulating Emulsions, <i>PDA Journal of Pharmaceutical Science &amp; Technology</i> 50: 372-77.   |          |
|                           | L47             | Studnicka et al., 1994. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. <i>Protein Eng.</i> 7:805-814.   |          |
|                           | L48             | Taylor et al., 1984. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. <i>Immunology.</i> 52(1):137-42.   |          |
|                           | L49             | Taylor et al., 1992. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. <i>J Gen Virol.</i> 73 (Pt 9):2217-23.  |          |
|                           | L50             | Van Wyke Coelingh et al., 1985. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. <i>Virology</i> 143(2):569-582.  |          |
|                           | L51             | Verma et al., 1997. Gene therapy - promises, problems and prospects, <i>Nature</i> 389:239-242.  |          |
|                           | L52             | Wald et al., 1988. In re ribavirin: a case of premature adjudication? <i>J. Pediatr.</i> 112(1):154-158.   |          |
|                           | L53             | Walsh et al., 1984. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. <i>Infect Immun.</i> 43(2):756-8.   |          |
|                           | L54             | Watkins et al., 1997. Determination of the relative affinities of antibody fragments expressed in <i>Escherichia coli</i> by enzyme-linked immunosorbent assay. <i>Anal Biochem.</i> 253(1):37-45.   |          |
|                           | L55             | Wright et al., 1982. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. <i>Infect. Immun.</i> 37(1):397-400.  |          |
|                           | L56             | Wu et al., 2008. Immunoprophylaxis of RSV Infection: Advancing from RSV-IGIV to Palivizumab and Motavizumab in Human Antibody Therapeutics for Viral Disease. <i>Current Topics in Microbiology and Immunology</i> 317. Springer-Verlag Berlin Heidelberg, p. 103-123. |          |
|                           | L57             | U.S. Serial No. 10/900,230 (U.S. Publ. No. 2005/0002926) - Interview Summary dated 03/27/2009  |          |
|                           | L58             | U.S. Serial No. 09/796,848 (U.S. Publ. No. 2002/0098189) - Office Action dated 01/22/2009  |          |

LAI-3012585v2

|   |                        |
|---|------------------------|
| <b>EXAMINER SIGNATURE</b>   | <b>DATE CONSIDERED</b> |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                        |